Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ASTM-AASTROM BIOSCIENCES: STEM CELL RESEARCH -- Ignore unavailable to you. Want to Upgrade?

To: decent who wrote (146)	12/9/1998 10:08:00 PM
From: Bo Didley	Respond to of 1084

GERN has no product. ASTM has a product. There is a big difference! ASTM is beyond the development stage. The AastromReplicell(TM) System> is an automated clinical system designed to enable hospitals to produce patient-specific cells for use in the treatment of a broad range of diseases including cancer, infectious diseases, auto-immune diseases as well as cells used in the restoration of solid tissues.(like gern) ...........but.....ASTM has a product NOW that SAVES LIVES !! better than GERN...better than ENMD ASTM is also going to the CANCER CONFERANCE this week. bo

To: decent who wrote (146)	12/9/1998 11:27:00 PM
From: Panita	Read Replies (1) \| Respond to of 1084

We are sitting below the IPO price. ASTM has reached the third base and is just a few steps away from home plate and the fruits of their work. We can consider ourselves lucky to have this gift. We can buy this stock now when the fruit is ripe for the eating. We should be glad that we can buy now below or around the IPO price. One big different between ASTM and the likes of GERN is that ASTM products are around corner; GERN products are year away. ENMD went from low single digits to high of 80's within hours. ASTM with viable products now is a better story. Furthermore it is great to own a company that is saving lives.